ERBB2 and breast carcinoma: Different combinatorial regimes have been approached; thus, the combination of gefitinib with calcitriol or their synthetic analogs resulted in a greater antiproliferative effect than with either of the agents alone in EGFR and HER2 positive breast cancer cells.